Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.
about
Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical PracticeOvarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for PreventionThe molecular fingerprint of high grade serous ovarian cancer reflects its fallopian tube originSociety of Gynecologic Oncology recommendations for the prevention of ovarian cancerSalpingectomy as a means to reduce ovarian cancer riskPathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.Occult tubal carcinoma found at risk reducing salpingectomy in a BRCA1 carrierOpportunistic salpingectomies for the prevention of a high-grade serous carcinoma: a statement by the Kommission Ovar of the AGO.Precursors of ovarian cancer in the fallopian tube: serous tubal intraepithelial carcinoma--an update.Characterization of precursor lesions in the endometrium and fallopian tube epithelium of early-stage uterine serous carcinomaShould Fallopian Tubes Be Removed During Hysterectomy Procedures? - A Statement by AGO OvarRisk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act.Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers.Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionalsOpportunistic salpingectomy for ovarian cancer preventionPrimary peritoneal cancer in BRCA carriers after prophylactic bilateral salpingo-oophorectomy.Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC)Small fallopian tube carcinoma with extensive upper abdominal dissemination: a case report.Pathogenesis and heterogeneity of ovarian cancer.Hereditary gynaecological malignancies: advances in screening and treatment.Hereditary breast cancer syndromes and genetic testing.Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study.Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management.Physicians' Perspectives and Practice Patterns Toward Opportunistic Salpingectomy in High- and Low-Risk Women.Risk-reducing salpingectomy: Let us be opportunistic.Detection of serous precursor lesions in resected fallopian tubes from patients with benign diseases and a relatively low risk for ovarian cancer.Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas.Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers."Best practices in risk reducing bilateral salpingo-oophorectomy: the influence of surgical specialty".Risk reduction surgery (RRS) for tubo-ovarian cancer in an Irish gynaecological practice: an analysis of indications and outcomes.Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices.
P2860
Q26740622-A8B67889-25F2-40A9-A567-DE8BAF8BE796Q26747279-46258430-B23F-433E-B67E-3B5690EDC929Q27008375-4A5DA537-6FE5-44D5-9075-CD4F691CD54DQ27009306-991A00A8-9A02-4B0D-93C1-ABA3D55A4502Q27011949-A105857F-7F8E-4C65-87FF-B937D24C5D04Q30370475-2B7BDA8F-23D4-452D-A521-0C74B332E471Q33563675-4008D0CA-63F2-455F-80E4-98B5D5D24007Q34473693-2076CDB9-A5E1-4AA2-B11D-76471F87658FQ35155614-C002B793-3A45-4B49-BAD7-E323B126E434Q35519808-BBF055CE-577F-487D-B8DB-96D98708E212Q35624638-3D9D5231-8385-4310-A09C-E639F01B80C9Q36313479-97BF1853-049D-43BD-B9BA-13067F36595CQ36634141-43FE8752-CE43-41D8-AE8F-18D8E0A3658AQ36904144-7999B97D-F49F-47A1-9264-E938DD66D3E3Q36938143-D1446F23-896D-4750-846F-081147CC2039Q37042357-BCD95510-5E4B-4DBE-8EDF-97B967BF6D3FQ37163464-81F8890F-DD34-40E3-BED5-C617A78171C1Q37329307-78325E21-797E-436B-9D7C-25CFC9F400C4Q37546692-70C967B3-A6EB-42CE-AE18-1C6F51D8BF45Q38067433-2C38AC63-193F-4C7F-8490-C5B385BFC19FQ38266306-CD4D07C5-FBE7-4650-AC5A-6967EF3D946FQ38964976-9ADD354E-0F69-49DC-BB9A-5385767FD735Q38978839-E99C7E53-E172-40ED-B0A6-4E1D3048D33FQ39059025-88E5226C-04BD-45B8-AC7D-C891238E43DAQ39196159-83B638BD-FD17-44F3-BE66-52B37804F88DQ39718281-DB230D0A-DDB1-4686-928F-FC7F598B8577Q43158887-7B359E42-495E-4ACC-8658-D2D6AA9F8260Q44498721-FB08B7C7-C679-4E99-A80C-8E1541014453Q47162185-4549B7B1-73B1-4B8E-A848-2FC4B98DFC07Q47180579-567CA26E-8C8D-4E85-BB0F-98F9AD722CC0Q50209189-E484C8F2-A0A7-4F53-9E43-4C0D978DD8FE
P2860
Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Risk-reducing salpingo-oophore ...... urgical-pathological protocol.
@en
Risk-reducing salpingo-oophorectomy
@nl
type
label
Risk-reducing salpingo-oophore ...... urgical-pathological protocol.
@en
Risk-reducing salpingo-oophorectomy
@nl
prefLabel
Risk-reducing salpingo-oophore ...... urgical-pathological protocol.
@en
Risk-reducing salpingo-oophorectomy
@nl
P2093
P1476
Risk-reducing salpingo-oophore ...... urgical-pathological protocol.
@en
P2093
Beth Crawford
C Bethan Powell
Charles Zaloudek
Dan H Moore
Jane McLennan
John Ziegler
Joseph T Rabban
Lee-may Chen
P304
P356
10.1097/IGC.0B013E31821BC7E3
P577
2011-07-01T00:00:00Z